GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Spectrum Pharmaceuticals, Inc. (SPPI) [hlAlert]

Rating:
Mkt Outperform
SPPI
up 101.88 %

Spectrum Pharmaceuticals, Inc. (SPPI) rated Mkt Outperform with price target $8 by Rodman & Renshaw

Posted on: Wednesday,  Oct 14, 2009  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) on 10/14/2009. Previously Rodman & Renshaw rated Buy Spectrum Pharmaceuticals, Inc. (NASDAQ:
SPPI) on 10/31/2007., when the stock price was $3.71. Since then, Spectrum Pharmaceuticals, Inc. has gained 101.89% as of 12/04/2015's recent price of $7.49.
If you would have followed the previous Rodman & Renshaw's recommendation on SPPI, you would have gained 101.88% of your investment in 2956 days.

Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company?s product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/14/2009 8:25 AM Buy
None
4.56 8.00
as of 12/31/2009
1 Week up  41.96 %
1 Month up  44.54 %
3 Months down  -5.49 %
1 YTD up  326.84 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/31/2007 11:25 AM Buy
None
3.71 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy